Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering ...

Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries ...

Epidemiological studies have linked dirty air to dementia and other brain disorders. Now researchers are trying to determine ...

An investigational induced pluripotent stem cell-derived CAR natural killer cell therapy was well tolerated both as ...

In a recent study, researchers from Uppsala University have shown that the Semliki Forest virus enters the central nervous ...

Researchers sought to determine whether CNS bridging radiotherapy would improve responses to CAR-T therapy in patients with B-cell lymphomas.

Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th- National Comprehensive Cancer ...

University at Buffalo researchers reveal molecular insights into the neurotoxic effects of PFAS. Per- and polyfluorinated ...